Agitation,Psychomotor Clinical Trial
Official title:
The Effect of Intraoperative Magnesium Sulfate Infusion on the Occurrence of Emergence Agitation After Pediatric Ophthalmic Surgery
Verified date | September 2023 |
Source | Seoul National University Bundang Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study designed to evaluate the correlation between the effect of intraoperative magnesium sulfate infusion and the incidence of emergence agitation after pediatric ophthalmic surgery
Status | Completed |
Enrollment | 92 |
Est. completion date | December 19, 2018 |
Est. primary completion date | December 19, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 4 Years to 7 Years |
Eligibility | Inclusion Criteria: - pediatric patients who are planned to operate ophthalmic surgery under general anesthesia aged 4-7 years Exclusion Criteria: - ASA class = III - imbalance of electrolyte - myocardial damage or conduction abnormality on ECG - myasthenia gravis or any other neuromuscular disease - impaired renal function - denial to participate in study or not be able to give informed consent |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam-si |
Lead Sponsor | Collaborator |
---|---|
Seoul National University Bundang Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the incidence of emergence agitation (EA) | Using PAED (pediatric anesthesia emergence delirium) score, consider the score 10 or more as occuring of EA. Comparing the score between the placebo group and the intervention group for the difference of the incidence of EA. | 15 minute interval at the post-anesthetic care unit (PACU) | |
Secondary | the severity of EA | Comparing the maximal PAED score between the placebo group and the intervention group for evaluating difference of severity of EA. | 15 minute interval at the post-anesthetic care unit (PACU) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03110900 -
Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
|
Phase 4 | |
Completed |
NCT05272501 -
CAlming Touch for People With Agitation or Other Behavioural Symptoms of DEMentia - A Randomized Feasibility Trial
|
N/A | |
Completed |
NCT06041646 -
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
|
Phase 4 | |
Completed |
NCT06217146 -
A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.
|
N/A | |
Recruiting |
NCT05543681 -
IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's
|
Phase 2 | |
Recruiting |
NCT03513549 -
Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder
|
||
Active, not recruiting |
NCT05658510 -
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
|
Phase 3 | |
Not yet recruiting |
NCT05612711 -
Dronabinol for Agitation in Dementia Crossover Trial
|
Phase 2 | |
Recruiting |
NCT04957238 -
Physical Restraints in Intensive Care Unit Patients
|
N/A | |
Terminated |
NCT03899506 -
Olanzapine Versus Midazolam for Agitation
|
||
Completed |
NCT03211897 -
Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation
|
N/A | |
Recruiting |
NCT05783505 -
A Multicomponent Intervention Program to Prevent and Reduce ICU Agitation and Physical Restraint Use
|
N/A | |
Completed |
NCT04053426 -
Agitation Follow up After Introduction of a New Patient Care Algorithm
|
||
Completed |
NCT03226522 -
Addressing Dementia Via Agitation-Centered Evaluation
|
Phase 2/Phase 3 | |
Recruiting |
NCT03926520 -
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)
|
N/A | |
Recruiting |
NCT04075435 -
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
|
Early Phase 1 | |
Completed |
NCT04276883 -
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
|
Phase 3 | |
Completed |
NCT04797715 -
Assessing Clinical Outcomes in Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT04251910 -
Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
|
Phase 1/Phase 2 | |
Recruiting |
NCT05765162 -
Safe Brain Initiative, Operationalizing Precision Anaesthesia
|